Radiation optic neuropathy (RON) is characterized by the rapid onset of painless irreversible vision loss in one or both eyes. We report 4 consecutive patients who presented with unilateral or asymmetric bilateral RON. All had bilateral optic nerve enhancement on MRI and were treated with hyperbaric oxygen (HBO) and oral corticosteroids. In the less affected eye, 2 of the 4 patients had preservation of vision, while in the other 2 patients, vision declined. No patient showed improvement in the more symptomatic eye, and in 2 patients, there was a significant decline in visual acuity. Our findings suggest that prompt treatment with HBO and oral corticosteroids may result in visual preservation in the less affected eye despite the presence of optic nerve enhancement on MRI.
This review compares and contrasts the surgical management options for IIH.
IntroductionSurgical Site Infection (SSI) after knee arthroplasty is a major cause of morbidity and mortality that increases the hospital stay, financial burden and mental anguish of the patient. Infection Control Unit at Aga Khan University Hospital (AKUH) incorporated total knee arthroplasty in its surgical care surveillance program and started collecting data in June 2012. The purpose of this study is to review Surgical Site Infection (SSI) rates in patients undergoing primary total knee replacement (TKR) surgery.Patients and methodologyAll patients from June 2012 to December 2013 undergoing knee arthroplasty at our hospital were included. Data was acquired from the hospital SSI database for knee arthroplasty surgery. Data was collected by SSI nurses for inpatients a well as post-discharge monitoring in clinics till 90 days post-op follow-up. The work has been reported in line with the PROCESS criteria.ResultsDuring this time period a total of 164 patients had primary TKR at AKUH. Out of these, 85 patients (52%) had bilateral TKR while 79 (48%) had unilateral TKR. The overall SSI was in 2 patients (1.2%).ConclusionIdentifying SSIs is multidimensional. Since our 2 infected cases after TKR occurred after discharge, this highlights the importance of post-discharge surveillance and not limiting the surveillance for inpatients only. Furthermore, the SSI program may be effective in controlling postoperative wound infections.
Study Objective-To describe (1) the treatment interval for adolescent females with Chlamydia trachomatis (CT), Neisseria gonorrhoeae (GC), or Trichomonas vaginalis (TV); (2) the proportion treated in ≤7 days; and (3) factors influencing the treatment interval.Design and Participants-Charts of sexually active females from an urban teen health center who participated in a larger study and were positive for CT, GC or TV (N = 58) were retrospectively reviewed for dates of treatment, and compared to demographic and symptom data. The treatment interval was defined as days from visit to treatment. CT and/or GC were analyzed together (CT/GC) because presumptive treatment covered both infections, and the diagnostic test (nucleic acid amplification) differed from that of TV (wet mount or culture).Results-The median treatment interval was 0 days for TV, 5 days for CT/GC, and 3 days for any STI. Overall, 39 (69%) were treated within 7 days of their visit. Those with TV were more likely than those with CT/GC to receive treatment at their initial visit (58 vs. 6%). Genitourinary symptoms increased the odds of treatment in ≤7 days. The treatment interval was significantly shorter for subjects who had their prescriptions phoned to a pharmacy than for those who returned to clinic for treatment (median 2.5 vs. 8 days).Conclusions-Where presumptive treatment is uncommon, providers were more likely to prescribe same day therapy to symptomatic patients or those with TV on wet mount. Additional strategies are needed to improve the proportion of adolescent females treated in ≤7 days.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.